Table 3 Ongoing clinical trials of new drug groups in AIHA
From: Autoimmune hemolytic anemia: current knowledge and perspectives
Intervention/ treatment | Group of agents | Condition or disease | Phase of study | |
|---|---|---|---|---|
Sirolimus plus ATRA | mTOR inhibitor plus tretinoin | refractory AIHA | 2 and 3 | NCT04324411 |
Idelalisib vs. ibrutinib | PI3Kδ inhibitor vs. BTK inhibitor | autoimmune cytopenia in the course of CLL | retrospective | NCT03469895 |
Parsaclisib | PI3Kδ inhibitor | AIHA | 2 | NCT03538041 |
Ibrutinib | BTK inhibitor | steroid refractory warm AIHA | 2 | NCT03827603 |
refractory/relapsed AIHA | 2 | NCT04398459 | ||
Ibrutinib or idelalisib | BTK inhibitor | AIHA associated with CLL | retrospective | NCT03469895 |
Interleukine-2 | cytokine | resistant, warm AIHA | 1 and 2 | NCT02389231 |
Low dose rituximab plus alemtuzumab | anti CD20 antibody plus anti CD52 antibody | refractory autoimmune cytopenias | 2 and 3 | NCT00749112 |
Fostamatinib | SYK inhibitor | warm AIHA | 3 | NCT03764618 |
2 | NCT02612558 | |||
SYNT001 (ALXN1830) | anti-FcRn antibody | warm AIHA | 1 and 2 | NCT03075878 |
SYNT001 (ALXN1830) vs. placebo | 2 | NCT04256148 | ||
M281 | 2 and 3 | NCT04119050 | ||
RVT-1401 | 2 | NCT04253236 | ||
Levamisole plus prednisolone | immunomodulatory drug plus GKS | warm AIHA | 2 | NCT01579110 |
BIVV009 (Sutimlimab) | complement C1 inhibitor | CAD | 3 | NCT03347422 |
3 | NCT03347396 | |||
APL2 | complement C3 inhibitor | warm AIHA, CAD | 2 | NCT03226678 |